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Abstract:  Medical applications of nanoparticular systems have attracted considerable 
attention because of their potential use in therapeutic targeting of disease tissues and their 
lower level of toxicity against healthy tissue, relative to traditional pharmaceutical drugs. 
The use of nanoparticular systems has been shown to overcome the limitations of most 
anticancer drugs in clinical applications. In particular, the improved performance of 
smarted nanoparticular system for solving the drug resistance problems that typically 
interrupt tumor treatment has provided a promising strategy for successful tumor 
chemotherapy. This review highlights recent studies that have examined the therapeutic 
effect of nanoparticular systems on drug-resistant tumors and presents insight on how   
they work.  
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1. Introduction 
 
Cancer is a major worldwide public health problem. Currently surgery, radiotherapy, and 
chemotherapy are all used to treat different forms of cancer. They can each be used alone or together 
depending on a number of factors such as the type, location, and spread of the cancer [1,2]. In 
particular, chemotherapy still remains the primary modality for treating cancers. Controlling the 
treatment dose to balance effective anticancer activity and toxicity plays an important role in the 
success of chemotherapy [3,4]. However, one of the major problems with chemotherapy is damage to 
surrounding healthy organs and tissue because many anticancer drugs are designed simply to destroy 
cells. The threat of severe side effects caused by the random distribution of the drugs throughout the 
body has meant that maximum dosages must be restricted [5,6].  
Another problem associated with the use of chemotherapy for cancer treatment is resistance against 
anticancer drugs [7-9]. Many types of wild cancers respond well to chemotherapy drugs in the 
beginning but show acquired resistance later [7-9]. The resistances of cancers that have been exposed 
to one cytotoxic agent develop cross-resistance to a whole range of drugs with different structures and 
cellular targets [7-9]. Once resistance appears, using higher drug doses to overcome resistance is 
ineffective because serious toxic effects appear and resistance is further stimulated [7-9].  
It has been established that general nanoparticular systems can be used to decrease the non-specific 
toxicity of anticancer drugs by ‘hiding’ the drug in the core of the nanoparticular system and 
controlling drug uptake in normal tissues, which is similar to the ‘Trojan horse’ concept [11-13]. 
However, their therapeutic effects in regards to drug resistance were not significant.  
A solution to overcome the problems of chemotherapy is the development of more advanced drug 
delivery systems for anticancer agents [10] that aim to improve the therapeutic efficacy for drug 
resistant tumors and patient compliance, and reduce toxic/side effects. In this review, several examples 
of advanced nanoparticular systems that have been developed to overcome drug resistance in tumors, 
which is a major hurdle for successful chemotherapy, are described. 
 
2. Drug Resistance in Tumors 
 
2.1. Multidrug Resistance (MDR) in Cells 
 
Drug resistance in tumors can occur due to both impaired drug delivery to the cancer tissue and the 
defense mechanisms of the cancer cell itself [14]. In general, broad-based drug resistance, either 
intrinsic or acquired, exists in tumors and is believed to be caused multifactorially (Figure 1). This has 
significantly hindered clinical efforts to formulate effective chemotherapy strategies against several 
blood cancers, as well as solid cancers associated with breast, ovarian and lower gastrointestinal tract 
cancers [15-18]. Until recently, various tissue culture studies have consistently shown that MDR in 
most cultured cancer cells involves ATP-binding cassette (ABC) transporters in the human such as  
P-glycoprotein (P-gp, ABCB1) [19-21], multidrug resistance protein (MRP, MRP-1/ABCC1) [22-24], Int. J. Mol. Sci. 2009, 10                 
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breast cancer resistant protein (BCRP, ABCG2) [25], lung resistant protein (LRP) [26-28], bcl-2 [29], 
p53 [30,31], Topoisomerase II (TopoII) [32,33], etc.   
 
Figure 1. Drug-resistance mechanisms (such as P-gp, MRP, BCRP, LRP, p53, bcl-2, and 
TopoII) in tumor cells. See text for details. 
 
 
 
P-gp, which is encoded by the MDR1 gene, is an ABC transporter normally involved in the 
excretion of toxins from cells using energy from ATP hydrolysis [19-21]. Generally, P-gp is expressed 
in normal tissues (such as immune-response cells, epithelial cells of colon, kidney, adrenal, pancreas, 
and liver) as part of the defense mechanism of the body [19]. When chemotherapy agents cause DNA 
damage in tumor cells, P-gp is over-expressed due to the activation of MDR1/ABCB1 (one of two 
isoforms of P-gp). Cells that over-express P-gp in the cellular membrane have been reported to display 
a strong drug resistance against a whole range of lipophilic drugs [20-21]. MRP-1 or BCRP is another 
member of the ABC transporter [22-25]. They are located on the cellular membrane or cytoplasmic 
vesicles and appear to transport lipophilic or anionic drugs outside of cells [22-24]. Although the 
hydrophobic vacuum cleaner model was proposed to evacuate drugs due to the interaction of P-gp with 
drugs partitioned into bilayer [24], the mechanism behind this function has not yet been well 
established. LRP is localized in cytoplasmatic vaults for sequestration of anticancer drugs into acidic 
vesicle from the cytoplasm [26-28]. Most of the vaults are located in the cytoplasm, but a portion of 
the vaults is present in the nuclear membrane or nuclear pore complex [26]. Due to the probability of 
LRP localization in these vaults, LRP has the ability to transport substrates from the nucleus to the Int. J. Mol. Sci. 2009, 10                 
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cytoplasm. Thus, the sequestered drugs could not promote DNA damage [27,28]. Furthermore, LRP 
can remove anticancer drugs from cells via exocytosis of acidic vesicles containing the trapped 
anticancer drugs [26,27]. In addition, LRP and P-gp might share a similar regulatory mechanism 
mediated by p53 [28]. 
Apoptosis, or programmed cell death (PCD), is a cellular self destruction mechanism involved in a 
variety of biological events, such as developmental sculpturing, tissue homeostasis, and the removal of 
unwanted cells [29-31]. Many anticancer drugs potentially induce PCD [1-5]. The balance of factors 
promoting and protecting PCD (e.g., p53, bcl-2, Bax/Bak) is a decisive component regulating the 
intrinsic chemosensitivity of a cell [29-31]. Resistance to PCD induced by chemotherapeutic drugs is 
assumed to involve mainly the over-expression of bcl-2 family members and the loss of wild-type p53 
[30]. When bcl-2 (anti-apoptosis factor) is over-expressed, the formation of apoptosome (consisting of 
Apaf-1, cytochrome c, and caspase) in drug-treated tumor cells may be blocked by the following 
cellular responses: i) inhibiting the release of cytochrome c from the mitochondria and preventing 
binding of cytochrome c and Apaf-1, ii) directly combining with Apaf-1, iii) directly binding several 
caspases and preventing caspase activation [29]. In addition, the DNA-binding transcription factor p53 
medicates a block of cell cycle entry into S phase in order to repair DNA damages and to activate a 
PCD pathway for serious DNA damages. Thus, the loss of wild-type p53 leads to both genomic 
instability and resistance to PCD by activating Bax/Bak (pro-apoptotic factors) from the mitochondria, 
which prevents the cell death process from occurring [30,31].  
Topoisomerases (Topo) are essential nuclear enzymes that can change the topological state of the 
DNA by breaking and rejoining the DNA phosphodiester backbone. Many anticancer agents have 
targeted Topo II [32]. When DNA is damaged by anticancer drugs, Topo II also breaks DNA double 
helices and promotes the formation of a cleavable complex that ultimately leads to cell death [32]. 
However, a reduction in the level of Topo II in MDR tumors due to the aberrant transcript by 
mutations, and posttranslational modification, cells leads to a decrease in the formation of the 
cleavable-complex, thereby preventing apoptosis of tumor cells [32,33].  
 
2.2. Drug-Resistance in Microenvironment of Tumors 
 
Drug resistance due to the microenvironment of tumors is one of the most important obstacles to 
tumor treatment (Figure 2). In clinical tumors, it is difficult to deliver oxygen and other nutrients to 
tumor cells because the tumor cells are located in a poorly organized vasculature and are far from 
blood vessels [34]. This hypoxic region is resistant to chemotherapy because drug penetration into this 
region is very limited [34]. Since tumor cells in this hypoxic region are non-proliferating or slowly 
proliferating with increasing distance from tumor blood vessels, most anticancer drugs are less active 
[34]. It has been reported that this region modulates the elevation of anti-apoptosis proteins to prevent 
cell death and the up-regulation of growth factors for cell growth [35]. In particular, several growth 
factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth 
factor (IGF), and hepatocyte factor (HGF), have important functions in regards to MDR, cell 
proliferation, metastasis, and angiogeneis [35,36]. These growth factors are closely related to 
chemoresistance, although there are several reports that these growth factors conversely enhance the 
chemosensitivity [37-39]. As shown in Figure 2, binding of EGF, FGF, and IGF to their receptors Int. J. Mol. Sci. 2009, 10                 
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leads to up-regulation of anti-apoptotic proteins (bcl-2 family members such as bcl-2, bcl-XL, and 
LAPs), resulting in inhibiting apoptosis. In addition, binding of FGF to its receptor mediates 
obstructing p53 pathways. HGF binding to its receptor enhances the DNA repair function, which is 
related to anti-apoptotic function [35-39].  
 
Figure 2. Drug-resistance mechanisms (such as soluble growth factors, ECM-based drug 
resistance, cell-cell interaction, and hypoxia-induced drug resistance) in the tumor 
microenvironment. See text for details.  
 
 
On the other hand, altered expression of extracellular matrix (ECM) components (such as 
fibronectin, collagen, tenacin, laminin, and hyalurona) contributed to protecting tumor cells from 
anticancer drugs, by activation of MAPKs and PI3K/AKT survival signaling, decreasing TopoII level, 
and arresting cell proliferation due to the increased cyclin-dependent kinase (CDK) inhibitor   
p27/Kip1 protein [39-41]. In addition, cadherins, selectins, and cell adhesion molecules (CAMs) can 
make cell-cell contact and exhibit further drug-resistance [41,42].  
Most importantly, the role of the microenvironment in the drug-resistance of tumors is multi-
factorial [34-42]. Growth factors modulate the drug-resistance of cancer cells and usually activate 
changes in adhesion molecules [35-38]. The adhesion molecules such as Cadherin promote the 
signaling of soluble factors, which induce the anti-apoptotic factors [39-42]. Tumor cells adherent to 
ECM components attenuate growth factor-mediated cancer cell protection [39-42]. Hypoxia increases 
anti-apoptotic proteins (e.g., bcl-2, bcl-XL, IAP family members), arrests cell cycle (due to increased 
CDK inhibitors p27/Kip1 and p21/Clip1), and elevates glutathione S-transferase- level (associated Int. J. Mol. Sci. 2009, 10                 
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with tumor progression and invasion). In addition, hypoxia through hypoxia-induced factor-1 (HIF-1) 
exhibits the expression of ATP-binding cassette drug effluxes (P-gp and BCRP). On the other hand, 
hypoxia modulates the tumor microenvironment by up-regulating vascular endothelial growth factor 
and its receptors, and facilitates aggressive proliferation of tumor cells with genetic instability [34,35]. 
 
3. Overcoming Drug-Resistance 
 
3.1. Using P-gp Modulators 
 
The identification of verapamil as a P-gp blocking agent inspired numerous investigations into 
discovering MDR inhibitors [43]. Various chemo-agents such as cyclosporine A, glibenclamide, 
PSC833, GF120918, XR9576, LY335979, etc have been developed to overcome MDR phenotypes in 
tumors [43-48]. Studies on minimizing pharmacokinetic interactions with anticancer drugs have also 
been conducted [49]. However, these chemo-agents have not yet been effective in Phase III trials  
[43-49]. In most cases, the ability of P-gp blocking chemo-agents to prevent the action has been 
examined in in vitro tumor cells, even though quite a few clinical trials involving P-gp reversal agents 
[43]. However, MDR in in vivo cancer cells results from multiple drug-resistant mechanisms and it is 
not caused by just P-gp [43-49]. P-gp blocking chemo-agents can also interact with the P-gp of healthy 
organs such as placenta, kidney, liver and kidney, resulting in more toxic effects of a given anticancer 
drug [43-50]. PSC833 (P-gp blocking chemo-agent) failed Phase III trials [50] because of these causes. 
Kabanov’s group has used Pluronic
 block copolymers, instead of chemo-agents, to interrupt the P-gp 
mediated drug efflux pump [51,52]. Pluronic formulations with anticancer drugs, below their critical 
micelle concentration (CMC), have been claimed to be effective in treating MDR tumors [51,52]. 
These results have been linked to the ability of Pluronic
 (PEO-PPO-PEO) block copolymers to cross 
the plasma membrane and suppress ATP production, although the mechanism of this function is still 
unknown. This effect has also been linked with gene modulation by Pluronic
 block copolymers 
[51,52]. This formulation seems to be effective with MDR tumors but interestingly it is less effective 
with wild tumors [51,52]. In addition, Pluronic formulations lack tumor specificity and not much is 
known about its influence on normal cells expressing P-gp.  
 
3.2. Using Nanoparticular Systems 
 
Many groups have studied the ability of a variety of nanoparticular systems to overcome MDR for 
tumor treatment (Table 1). Compared to conventional chemo-therapy, nanotherapeutic systems have 
several potential advantages for cancer treatment, including easy modification of particle surface for 
targeting systems, increased stability in blood, dual delivery such as drug, gene, and/or imaging agents, 
drug delivery system responding to environmental stimuli such as temperature, pH, salt, and 
ultrasound, etc. These systems include liposomes, polyalkylcyanoacrylate nanoparticles, polymeric 
micelles system, etc [53-76]. 
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Table 1. Reversal of drug-resistance by nanoparticular systems. 
Nanoparticular formulation  Drug-resistance target  Feature   Ref. 
Pluronic
 micelle with ultrasound 
treatment 
Enhancing drug uptake by 
ultrasound treatment 
Possible to treat wild and 
drug-resistant tumors 
[63,64] 
Paclitaxel loaded mixed micelle system 
of Pluronic
 P105 and L101 
Inhibition of P-gp by 
Pluronic
 
Combined mechanisms of FR-
mediated endocytosis for 
tumor targeting 
[65] 
Liposomal formulation with 
doxorubicin/paclitaxel/valspodar 
Inhibition of P-gp by 
valspodar 
- [44] 
Liposomal topotecan with amlodipine  Inhibition of P-gp by 
amlodipine 
- [52] 
Liposomal doxorubicin/verapamil  Inhibition of P-gp by 
verapamil 
Verapamil affected 
pharmacokinetics of 
doxorubicin in vivo 
[56] 
Liposomal doxorubicin/Pluronic
 F68  Inhibition of P-gp by 
Pluronic
 
- [54] 
Liposomal doxorubicin/antisense 
oligonucleotides 
Targeted to bcl-2 mRNA 
and MDR1 mRNA 
Overcoming bcl-2 and P-gp  [58] 
Polyalkylcyanoacrylate nanoparticles 
with doxorubicin and cyclosporin A 
Enhancing drug uptake by 
unknown mechanisms of 
polyalkylcyanoacrylate 
nanoparticles  
Cyclosporin A can affect 
pharmacokinetics of 
doxorubicin 
[59,60] 
Daunorubicin loaded Fe3O4 
nanoparticles 
Enhancing drug uptake by 
Fe3O4 nanoparticles 
Interaction between Fe3O4 and 
unknown biological active 
molecules on the membrane 
of leukemia cells, increased 
drug uptake 
[74] 
Poly(ethylene oxide)-modified 
poly(epsilon-caprolactone) (PEO-PCL) 
nanoparticle with ceramide and 
paclitaxel 
Targeting to P-gp  Co-therapy (ceramide and 
paclitaxel) enhanced 
cytotoxicity for drug-resistant 
tumors 
[62] 
Transferrin receptor-targeting liposomal 
doxorubicin 
Evading P-gp function by 
transferring receptor-
mediated internalization 
pathway 
- [67] 
Folate-conjugated liposomal 
doxorubicin 
Evading P-gp function by 
FR-mediated internalization 
pathway 
No significant tumor-growth 
inhibition effect in in vivo 
animal model 
[68] 
pH-sensitive poly(L-histidine)-based 
micelle system with folic acid 
Enhancing cytoplasmic drug 
release due to proton-sponge 
effect of poly(L-histidine) 
In vivo animal studies showed 
significant tumor regression 
effect in drug-resistant tumors 
[69-73, 
75] 
 
First, one strategy using nanoparticular systems to overcome the MDR cancers is to formulate both 
anticancer agents and biological modification agents (such as P-gp inhibitors, ATP depletion Int. J. Mol. Sci. 2009, 10                 
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molecules, and cell membrane modifiers) into nano-systems. These systems primarily accumulate 
passively in solid tumors by a process termed ‘enhanced permeability and retention’ (EPR) effects 
[54]. Lu et al. have formulated topotecan (anticancer drugs) and amlodipine (P-gp blocking   
chemo-agent) into stealth liposomes [53]. It is known that amlodipine blocks Ca
2+channel through 
activation of caspase 8, caspase 3, and caspase 7, decreases intracellular Ca
2+ level, and acts as a 
substrate of P-gp [53]. First, this system has been shown to result in an accumulation in solid tumors 
by EPR effect. This system may then provide increased anticancer activity due to the P-gp inhibition 
of amlodipine [53]. Similarly, other groups have designed liposome/Pluronic
 F68 or 
liposome/verapamil systems, involving encapsulated doxorubicin (anticancer drug) [55,56]. These 
trials presented enhanced cellular uptake of nanoparticular systems due to pinocytosis and retention of 
anticancer drugs in in vitro tumor cells, followed by ATP depletion by Pluronic
 block copolymer or 
direct binding of verapamil to P-gp on specific sites [54,56]. However, it was also noted that blocking 
MDR using these systems actually required a high dose, which can increase toxicity and affect the 
pharmacokinetics of the anticancer drugs [56,57]. 
Minko’s group has developed PEGylated liposomes with doxorubicin and antisense 
oligonucleotides to target bcl-2 and P-gp [58]. This antisense oligonucleotides delivery system was 
shown to simultaneously inhibit the pumping mechanism in MDR cells and substantially enhance 
tumor apoptosis in mice bearing a xenograft of human MDR ovarian carcinoma [58], although the 
tumor targeting ability was not optimal and the practical development of a cytosolic antisense 
oligonucleotide delivery system was not satisfied.  
Couvreur’s group reported that polyalkylcyanoacrylate (PACA) nanoparticles with doxorubicin 
could reverse P-gp by modulating interactions between PACA nanoparticles and the cell surface 
[59,60]. However, the interaction mechanism of PACA nanoparticles with tumor cells remains unclear. 
Overall, it is questionable whether these investigations, which target a particular MDR type (such as  
P-gp), will be effective against in vivo MDR cancers that involve various MDR phenotypes. 
Recently, Au’s group introduced another strategy such as a tumor priming technique to enhance the 
anticancer delivery and efficacy of chemotherapy [61]. As mentioned above, the anticancer drugs are 
not effectively delivered into the hypoxia region due to the high density of solid tumors in clinic 
situation. They pretreated tumors with anticancer drugs, leading to the reduced cell density. 
Subsequent drug treatment allowed for drug penetration into the inner layers of a solid tumor. This 
tumor pretreatment (tumor priming) with paclitaxel (PAC) expanded the interstitial space and vessel 
diameter around tumors, increasing the doxorubicin-loaded liposomes (Doxil
®)’ anticancer activity 
and long-term survival rate [61]. This test suggests a potentially useful means to enhance the degree of 
tumor penetration by the nanoparticular system, even if the tumors exist in a hypoxic condition. 
However, the systems are in doubt to overcome MDR phenotypes related to molecular mechanisms 
such as ABC transporters. 
Rapoport  et al. have observed that a drug-loaded polymeric micelle system could efficiently 
delivery anticancer drugs to wild and MDR tumors using an ultrasound technique [63,64]. The 
ultrasound leads to the internalization of micelles rather than inducing mechanical damage to the 
cellular membrane [63,64]. Immediate cell killing by the ultrasonic impact was not observed in their 
experiments. Tumor cells were readily killed by the cytotoxic activity of the drug released from the 
micelles after they were internalized [63,64].  Int. J. Mol. Sci. 2009, 10                 
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On the other hand, several groups have tried to overcome the MDR by employing a drug delivery 
system modified with active targeting moiety. The systems could be expected to increase the 
intracellular drug concentration by avoiding the P-gp pathway through active internalization (e.g., 
receptor-mediator endocytosis) of the drug-loaded carriers.  Fang  et al. have studied taxol-loaded 
mixed micelle systems with Pluronic
 block copolymer P105 or L101 [65]. This system was modified 
with folic acid to target a variety of tumor cells over-expressing the folic acid receptor (FR). It is 
beneficial to concentrate drug-loaded micelles into solid tumors with FR [65,66]. However, the drug 
release from micelle into cytosol or nucleus was in doubt and there is a possibility of exocytosis, 
another MDR mechanism. Similarly, Kiwada et al. have reported transferrin receptor-targeting 
liposomal doxorubicin [67]. This formulation was anticipated to bypass P-gp over-expressed on 
cellular membranes because the internalization pathway, receptor-mediated endocytosis, is 
independent of the P-gp pathway. Alberto Gabizon et al. have also used the liposomal system with 
folic acid [68]. However, no significant tumor-growth obstruction was observed in these naoparticular 
systems, which may have been due to inefficient cytosolic anticancer drug release and lower drug 
concentration in the target sites such as the nucleus and mitochondria.  
Overall, these investigations have showed limited success in the states of in vitro or preclinic study. 
They have usually targeted a single MDR mechanism in tumors associated with various MDR 
mechanisms. As a result, no approach has been proven to be effective in clinical MDR tumor 
treatments so far. 
 
3.3. Smart Nanoparticular Systems 
 
For the reversal of complicated mechanism in MDR, smart nanoparticular system has been 
developed with the concept of ‘bunker buster’ using endosomal pH (<pH 7.0) targeting systems   
[69-76]. The smart nanoparticular system composed of targeting moiety and pH-sensitive blocks, 
effectively transport anticancer drugs into cytosol without detection of ABC transporters (due to 
receptor-mediated entocytosis of system) and with the breaking of endosome. The breaking of 
endosome is responsible for ‘proton sponge effect,’ which arises from a large number of weak 
conjugate bases (with buffering capabilities at pH 5-6), leading to proton absorption in acid organelles 
and an osmotic pressure buildup across the organelle membrane [77]. 
Lee  et al. have designed poly(L-histidine) (polyHis, Mw 5KDa)-b-poly(ethylene glycol) (PEG,   
Mw 2KDa) based nanoparticular micelle system with pH-responsive properties [69-72]. The polyHis 
is lipophilic and becomes deprotonated when the pH is above the pKb, while PEG is soluble in water at 
all pHs [69]. This amphiphilicity was responsible for the formation of self-assembly polymeric 
micelles [69-72]. Lowering pH of the solution below the pKb destabilized the micellar core structure 
due to that protonation of the polyHis [70]. Consequently, this micelle was disintegrated below pH 7.2 
due to the protonation of the polyHis block forming the micellar core [69]. The mixed micelle system, 
which was composed of polyHis-b-PEG (75 wt %) and poly(L-lactic acid) (PLLA, Mw 3KDa)-b-PEG 
(Mw 2KDa) (25 wt%) block copolymers decorated with folic acid (for FR-mediated tumor targeting), 
presented excellent colloidal stability at pH 7.0-7.4, but destabilized below pH 7.0, resulting from the 
incorporation of a non-ionizable block copolymer (PLLA-b-PEG) [70]. Interestingly, the mixed 
micelles were able to active intracellular translocation of the drug-carriers via specific interactions Int. J. Mol. Sci. 2009, 10                 
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such as FR-mediated endocytosis by escaping pumping out the administrated drugs by P-gp. The 
systems translocated as a formation of endosome could trigger drug release at endosomal pHs   
(pH < 7.0) [70,71]. The proton-sponge effect of polyHis also modulated endosomal disruption for 
cytoplasmic drug release [70,71]. These properties of the polyHis-based micelle system resulted in an 
enhanced drug concentration in cytoplasm or nucleus, which were successful in killing in vitro and in 
vivo tumor cells over-expressing P-gp [70,71]. The biodistribution of this system showed the more 
accumulation of drug in the MDR tumor compared to that of free drug [71].  
 
Figure 3. Schematic representation of the acid-induced pop-up targeting mechanism 
(PHSM
pop-upTAT) of the peptide-conjugated micelle corona. See text for details. Reproduced 
with permission from reference [73].  
 
 
 
On the other hand, Lee et al. have developed multifunctional pH-responsive polymeric micelle 
system (denoted as PHSM
pop-upTAT) for treating various MDR phenotypes [72,73]. Figure 3 describes 
the central concept of this polymeric micelle system with pH signals. The PHSM
pop-upTAT consisted of 
polyHis (Mw 5Kda)-b-PEG (Mw 3.4Kda) and PLLA (Mw 3KDa)-b-PEG (Mw 2KDa)-b-polyHis  
(Mw 2KDa)-TAT peptide. The shorter polyHis block (Mw 2KDa) was located at the interface of the 
micellar core [consisting of longer polyHis (Mw 5KDa) and PLLA] and TAT peptide block conjugated 
with shorter polyHis block was simultaneously buried in the PEG forest (hydrophilic shell). However, 
as the pH was lowered below pH 7.0, the degree of ionization of the shorter polyHis block increased 
and the TAT peptide block was gradually exposed to the outside of the hydrophilic shell [73]. It is 
known that the TAT peptide (non-specific cell penetrating peptide derived from human 
immunodeficiency virus type 1 and 2) serves to translocate nanoparticles into cells due to the   
energy-dependent endocytosis (or macropinocytosis) after electrostatic interaction [74]. The TAT 
peptide exposed on the surface of the micelle can provide active internalization of mixed micelles into 
cells, regardless of the broad heterogeneity of tumor cells. As a result, this system showed high 
accumulation of anticancer drugs in tumor cells and exhibited cytosplasmic drug release due to the 
proton sponge effect of longer polyHis block dissociated from PHSM
pop-upTAT at an endosomal pH 
[74]. These process sharply elevated the drug concentration to levels much higher than the cytotoxic 
threshold dose in tumor cells and helped to eliminate various MDR phenotypes (such as MRP, LRP, 
bcl-2 and TopoII) (Table 2) [73]. The IC50 of PHSM
pop-upTAT and the free drug is shown in Table 2. 
Furthermore, a novel virus-like nanogel (virogel) system that has infectious properties (just like virus) 
for wild and MDR tumor cells was developed based on the findings of this system [75].  Int. J. Mol. Sci. 2009, 10                 
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Table 2. IC50 of PHSM
pop-upTAT and free DOX for human promyelocytic leukemia   
drug-resistant HL-60/MX2 (with decreased TopoII level), human promyelocytic leukemia  
HL-60 (with bcl-2), human lung drug-resistant NCI-H69/AR (with MRP), and human 
ovarian tumor A549 (with LRP) cells (n=9). All experiments were performed at pH 6.8 
RPMI-1640/PBS medium. IC50 was obtained from the DOX concentration where 50% cell 
viability was achieved. Reproduced with permission from reference [73]. 
  PHSM
pop-upTAT Free  DOX 
HL-60/MX2 
a  0.32  0.07 g/mL 1.12   0.08 g/mL 
HL-60
 b  0.10  0.03 g/mL 0.42   0.07 g/mL 
NCI-H69/AR 
c  0.20  0.06 g/mL 0.75   0.08 g/mL 
A549 
d  0.75  0.08 g/mL 6.60   0.09 g/mL 
a: IC50 after 1-hour incubation with DOX-loaded formulation; b: IC50 after 1-hour incubation with 
DOX-loaded formulation; c: IC50 after 24-hour incubation with DOX-loaded formulation; d: IC50 
after 48-hour incubation with DOX-loaded formulation. 
 
Figure 4. Schematic presentation of the virogels. See text for details. Reproduced with 
permission from reference [76]. 
 
 
 
The virogel system is now one of the most promising nanoparticular delivery systems because this 
system has cell specific infection, injects a toxin, destroys MDR tumor cells, and migrates to 
neighboring MDR tumor cells with repeated cycles [75]. This system consists of a lipophilic core 
[poly(L-histidine-co-phenylalanine): poly(His-co-Phe)] and two hydrophilic shells [PEG and bovine 
serum albumin (BSA)]. One end of the PEG is linked to the core-forming block and the other is 
randomly linked to BSA, which forms a capsid-like shell (Figure 4) [76]; this structure is formed by an 
Oil-in-water emulsion method. It is worth noting that this system has a reversible swelling/deswelling 
property that is dependent on pH. The anticancer drug (doxorubicin) is released when the virogel is 
swelled at pH 6.4 (endosomal pH), but the rate of drug release is reduced when the virogel is in the 
deswelled state at pH 7.4-6.8 (cytoplasmic pH). Moreover, this system can physically disrupt the 
endosomal membrane due to the volumetric expansion (average particle size ~355 nm at pH 6.4) of the Int. J. Mol. Sci. 2009, 10                 
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virogel at endosomal pH. Thus, upon endosomal uptake and acidification the virogels release the drug 
and disrupt the endosomal membrane. The virogels then shrink in the cytoplasm in response to the 
cytoplasmic pH, and wait lysis of the tumor cell due to the release of the anticancer drugs in the 
endosome. The virogels then are released from the lysed cell and can subsequently infect neighboring 
tumor cells. Although further in vivo investigations are required, this nanoparticular system is believed 
to be a highly promising candidate for treating wild and MDR tumors. 
 
4. Conclusions 
 
Researchers have revolutionized the nanoparticular system for tumor treatment, especially in regards to 
overcoming MDR phenotypes in tumors. Nanosystems were tailor-made corresponding to the 
pharmaceutical demands, improved therapeutic effectiveness due to the combination therapy with multiple 
drugs. Some nanoparticular systems decorated with endogenous ligands, were internalized into tumor 
cells due to receptor-mediated endocytosis; thus, these systems were advantageous in that they 
bypassed P-gp over-expressed on the cellular membrane. Furthermore, the pH-responsive micelle 
systems were capable of achieving controlled drug release and endosomal escape, which were both 
vital in overcoming various MDR factors.  
Although several attempts at overcoming MDR have been studied in the various areas of cancer 
research, the results are not yet satisfied in clinical situation. Of course, it is not an easy task to treat 
MDR tumors associated with various MDR phenotypes. Nevertheless, these nanoparticular systems are 
expected to continually promote the creation of novel strategies for treating MDR tumor cells and will be 
instrumental in the development of novel chemo-agent.  
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